Empagliflozin Impurity II
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

Empagliflozin Impurity II

● In Stock

Catalogue No.:VE006517
CAS No.:N/A
Mol. Formula:C17H17ClO2
Mol. Weight:288.77 g/mol

Additional information on Empagliflozin Impurity II

Parent drug

Empagliflozin

IUPAC Name

(S)-3-(4-(2- Chlorobenzyl)phenoxy)tetrahy drofuran

Synonyms

N/A

Smiles

ClC1=CC=CC=C1CC2=CC=C(O[C@@H]3COCC3)C=C2

InChI

InChI=1S/C17H17ClO2/c18-17-4-2-1-3-14(17)11-13-5-7-15(8-6-13)20-16-9-10-19-12-16/h1-8,16H,9-12H2/t16-/m0/s1

Description

The compound Empagliflozin Impurity II a thoroughly characterized reference standard that complies with rigorous regulatory guidelines, including those from USP, EMA, JP, and BP. It is ideal for critical applications such as analytical method development, method validation (AMV), and quality control (QC), especially in the production of Empagliflozin. Designed to support both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA), this product delivers the precision required for reliable results. Additionally, it includes a detailed Structure Elucidation Report (SER), ensuring accuracy and dependability for advanced analytical purposes. It is a potent, highly selective, sodium-glucose cotransporter-2(SGLT-2) inhibitor. It is well-tolerated antihyperglycemic for the treatment of type-2 diabetes. It reduces renal reabsorption of glucose.

References

“Frampton, James E. “Empagliflozin: A Review in Type 2 Diabetes.” Drugs, vol. 78, no. 10, June 2018, pp. 1037–48, https://doi.org/10.1007/s40265-018-0937-z. ?Wanner, Christoph, et al. “Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.” New England Journal of Medicine, vol. 375, no. 4, July 2016, pp. 323–34, https://doi.org/10.1056/nejmoa1515920. ?”

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url